Cardio Diagnostics Holdings, Inc. (CDIO) Free cash flow
- Free cash flow · 12 months (USD): Value $-5.82M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -40307.52%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-5.82M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-5.66M − $164.59K ≈ $-5.82M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -40307.52% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-5.82M ÷ $14.45K × 100 ≈ -40307.52% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-5.66M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.87× | Operating cash flow / net income. Period ending 2026-06-30. $-5.66M ÷ $-6.47M ≈ 0.87× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -5.66M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 164.59K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -5.82M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 14.45K USD | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -6.47M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-5.82M | (m) | $-5.66M | $164.59K | (m) | $14.45K | (m) | $-6.47M | (m) | (m) | -40307.52% | 0.87× |
| 2026-03-31 | $-6.07M | (m) | $-5.89M | $183.29K | (m) | $16.57K | (m) | $-6.65M | (m) | (m) | -36657.01% | 0.89× |
| 2025-12-31 | $-5.91M | (m) | $-5.73M | $187.32K | (m) | $14.82K | (m) | $-6.50M | (m) | (m) | -39893.09% | 0.88× |
| 2025-09-30 | $-5.95M | (m) | $-5.76M | $190.96K | (m) | $15.78K | (m) | $-6.55M | (m) | (m) | -37689.99% | 0.88× |
| 2025-06-30 | $-5.57M | (m) | $-5.52M | $51.37K | (m) | $19.51K | (m) | $-6.25M | (m) | (m) | -28567.11% | 0.88× |
| 2025-03-31 | $-5.36M | (m) | $-5.16M | $200.57K | (m) | $19.90K | (m) | $-5.85M | (m) | (m) | -26935.59% | 0.88× |
| 2024-12-31 | $-5.21M | (m) | $-4.99M | $214.76K | (m) | $34.89K | (m) | $-8.38M | (m) | (m) | -14926.54% | 0.60× |
| 2024-09-30 | $-6.03M | (m) | $-5.29M | $748.18K | (m) | $35.69K | (m) | $-8.25M | (m) | (m) | -16909.51% | 0.64× |
| 2024-06-30 | $-5.91M | (m) | $-5.17M | $737.52K | (m) | $39.14K | (m) | $-8.77M | (m) | (m) | -15103.61% | 0.59× |
| 2024-03-31 | (m) | (m) | $-5.26M | (m) | (m) | $32.99K | (m) | $-11.51M | (m) | (m) | (m) | 0.46× |
| 2023-12-31 | $-6.25M | (m) | $-5.67M | $575.66K | (m) | $17.07K | (m) | $-8.38M | (m) | (m) | -36612.00% | 0.68× |
| 2023-09-30 | (m) | (m) | $-7.11M | (m) | (m) | $12.71K | (m) | $-9.37M | (m) | (m) | (m) | 0.76× |
| 2023-06-30 | (m) | (m) | $-7.45M | (m) | (m) | $2.67K | (m) | $-8.58M | (m) | (m) | (m) | 0.87× |
| 2023-03-31 | (m) | (m) | $-6.55M | (m) | (m) | $950.00 | (m) | $-5.40M | (m) | (m) | (m) | 1.21× |
| 2022-12-31 | (m) | (m) | $-5.09M | (m) | (m) | $950.00 | (m) | $-4.66M | (m) | (m) | (m) | 1.09× |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |